We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+32.23%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$295M
AUM Growth
-$39.7M
Cap. Flow
+$2.33M
Cap. Flow %
0.79%
Top 10 Hldgs %
98%
Holding
17
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
CALC icon
CalciMedica
CALC
+$2.38M

Top Sells

Rank Stock Value
1
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$51.2K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$188M 63.5%
6,068,125
– –
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.69B
$24.4M 8.26%
1,025,000
– –
VRNA
3
DELISTED
Verona Pharma
VRNA
$17.9M 6.07%
1,115,352
– –
ELEV
4
DELISTED
Elevation Oncology
ELEV
$14.5M 4.92%
2,834,910
– –
BMEA icon
5
Biomea Fusion
BMEA
$84.6M
$11.9M 4.04%
798,757
– –
GLUE icon
6
Monte Rosa Therapeutics
GLUE
$1.4B
$10.4M 3.51%
1,472,331
– –
NUVB icon
7
Nuvation Bio
NUVB
$2.2B
$9.25M 3.13%
2,541,009
– –
CMPS
8
Compass Pathways
CMPS
$1.53B
$8.02M 2.72%
964,500
– –
PSTX
9
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.33M 1.13%
1,043,267
– –
CALC icon
10
CalciMedica
CALC
$15.8M
$2.17M 0.73%
+521,114
New +$2.38M
OKUR
11
OnKure Therapeutics
OKUR
$154M
$1.47M 0.5%
88,608
– –
MRKR icon
12
Marker Therapeutics
MRKR
$18.8M
$1.35M 0.46%
314,286
– –
TECX
13
Tectonic Therapeutic
TECX
$529M
$1.29M 0.44%
84,148
– –
SPRB
14
Spruce Biosciences
SPRB
$118M
$948K 0.32%
16,073
– –
ACRS icon
15
Aclaris Therapeutics
ACRS
$726M
$539K 0.18%
434,455
– –
VIRX
16
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$294K 0.1%
288,571
– –
BCEL
17
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-387,653
Closed -$51.2K

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Aisling Capital Management held 17 positions worth $295M, down 12% from $335M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Aisling Capital Management's Q1 2024 filing shows 1 new and 1 closed positions. Its largest new stake was CalciMedica: 521,114 shares worth $2.17M. The largest sale was Atreca, Inc. Class A Common Stock, an estimated $51.2K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's largest Q1 2024 buy was CalciMedica: 521,114 shares worth $2.17M.
  • Aisling Capital Management fully exited Atreca, Inc. Class A Common Stock in Q1 2024, selling an estimated $51.2K.
  • Aisling Capital Management's ten largest holdings make up 98% of its $295M portfolio in Q1 2024.
  • Aisling Capital Management opened 1 new position and closed 1 in Q1 2024.
  • Aisling Capital Management's portfolio value fell 12% quarter-over-quarter to $295M.

Based on Aisling Capital Management's 13F filing for Q1 2024, filed 14 May 2024.